Ignite Creation Date:
2024-05-05 @ 11:33 AM
Last Modification Date:
2024-10-26 @ 9:09 AM
Study NCT ID:
NCT00072605
Status:
COMPLETED
Last Update Posted:
2019-12-17
First Post:
2003-11-04
Brief Title:
Experimental Ebola Vaccine Trial
Sponsor:
National Institute of Allergy and Infectious Diseases NIAID
Organization:
National Institutes of Health Clinical Center CC
Study Overview
Official Title:
VRC 204 A Phase I Clinical Trial to Evaluate the Safety and Immunogenicity of a Multiple Strain Ebola DNA Plasmid Vaccine VRC-EBODNA012-00-VP in Adult Volunteers
Status:
COMPLETED
Status Verified Date:
2007-08-22
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study will test the safety of an experimental vaccine developed to protect against Ebola virus infection and to determine if the vaccine induces an immune response to the virus The Ebola virus causes a disease called Ebola hemorrhagic fever Symptoms begin with fever and muscle aches and progress to breathing problems severe bleeding kidney problems and shock The infection may be mild but it can also lead to death The vaccine used in this study is made from small parts of Ebola genetic material It cannot cause Ebola hemorrhagic fever to develop in those who receive it
Healthy volunteers 18 to 44 years of age may be eligible for this study Candidates will be screened with a medical history physical examination and laboratory tests and complete an assessment of understanding questionnaire to show that they understand the study
Depending on their order of entry into the study participants are assigned to receive one of three vaccine doses or placebo The first group receives the lowest dose 2 milligram of vaccine or placebo If this dose is safe then the second group receives 4 mg and if this dose is safe the third group receives 8 mg Injections are given in a muscle in the upper arm Participants receive three injections each 4 weeks apart on study days 0 28 and 56
Participants record their temperature and symptoms in a diary card for 7 days following each injection They return to the clinic 2 to 3 days after each injection and then 2 weeks after each injection until study week 10 Additional follow-up visits are then scheduled at weeks 12 24 38 and 52 At each visit participants provide a blood and urine sample for testing and have their vital signs and lymph nodes checked their weight measured and their symptoms reviewed Additional laboratory tests may be requested between visits
Healthy volunteers 18 to 44 years of age may be eligible for this study Candidates will be screened with a medical history physical examination and laboratory tests and complete an assessment of understanding questionnaire to show that they understand the study
Depending on their order of entry into the study participants are assigned to receive one of three vaccine doses or placebo The first group receives the lowest dose 2 milligram of vaccine or placebo If this dose is safe then the second group receives 4 mg and if this dose is safe the third group receives 8 mg Injections are given in a muscle in the upper arm Participants receive three injections each 4 weeks apart on study days 0 28 and 56
Participants record their temperature and symptoms in a diary card for 7 days following each injection They return to the clinic 2 to 3 days after each injection and then 2 weeks after each injection until study week 10 Additional follow-up visits are then scheduled at weeks 12 24 38 and 52 At each visit participants provide a blood and urine sample for testing and have their vital signs and lymph nodes checked their weight measured and their symptoms reviewed Additional laboratory tests may be requested between visits
Detailed Description:
This is a Phase I randomized placebo-controlled dose-escalation study of an Ebola DNA plasmid vaccine The hypothesis is that the vaccine will be safe for human administration and elicit immune responses to Ebola Primary objectives are to evaluate the safety and tolerability of the investigational vaccine and the secondary objective is to evaluate immune responses Randomization assignment will be blinded to subjects clinical investigators and laboratory investigators
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 04-I-0028 | None | None | None |